CurebaseDemo
    New ArticleRead Article →
    Back to Resources

    Clinical Trial for Multiple Sclerosis: Patient Guide 2026

    clinical trial for multiple sclerosis

    The world of multiple sclerosis (MS) research is moving faster than ever, filled with hope and groundbreaking discoveries. At the heart of this progress is the clinical trial for multiple sclerosis, a carefully designed study that tests new treatments and strategies to slow the disease, repair damage, and improve quality of life. But the way these trials are designed and run has changed dramatically.

    Gone are the days of rigid, one size fits all studies. Today’s trials are smarter, more inclusive, and more focused on what truly matters to patients. Let’s explore the key concepts that define the modern landscape of MS research.

    The Evolving Blueprint of an MS Clinical Trial

    How a study is structured, or its design, is the foundation for everything. Over the past few decades, the blueprint for a clinical trial for multiple sclerosis has been completely upgraded.

    Moving Beyond Placebos

    In the early days of MS research, new drugs were often tested against a placebo (a sugar pill). This was necessary when no proven treatments existed. However, with more than a dozen effective disease modifying therapies (DMTs) now available for relapsing remitting MS (RRMS), it’s no longer considered ethical to leave patients on a placebo for long periods. Doing so could expose them to unnecessary relapses and disability.

    This ethical shift has led to the rise of the active comparator design. In these studies, a new investigational drug is tested head to head against an existing, approved therapy. This approach answers a more relevant question: Is this new treatment better than, or as good as, the current standard of care? This gives doctors and patients the real world data they need to make informed decisions.

    Combining Forces for Better Outcomes

    Another innovative approach is the combination therapy trial, which tests two or more treatments together. The idea is that therapies with different mechanisms of action, for example, one that reduces inflammation and another that promotes myelin repair, might work together to produce a stronger effect.

    While early attempts like the CombiRx study (which combined two existing therapies) showed limited additional benefit, the strategy remains a key area of interest. Future combination trials are exploring pairing powerful anti inflammatory drugs with new neuroprotective or remyelinating agents, aiming to tackle MS from multiple angles at once.

    Smarter, Faster, and More Patient Friendly Trials

    Researchers are constantly finding new ways to make clinical trials more efficient and less burdensome for participants. This has led to innovative structures that accelerate the path to discovery.

    Adaptive Trial Designs

    An adaptive design is a flexible trial structure that allows for planned changes based on incoming data. For example, a study might start with three different doses of a new drug. Halfway through, researchers can analyze the data and drop the least effective dose, focusing resources and new patient enrollment on the more promising options.

    A groundbreaking example is the UK’s Octopus trial for progressive MS. This multi arm, multi stage platform tests several treatments at once and uses interim data to quickly advance winners and drop losers, aiming to find effective therapies three times faster than traditional methods.

    Pragmatic (Real World) Trials

    A pragmatic trial is designed to see how a treatment works in a real world clinical setting, not just in the highly controlled environment of a conventional study. These trials have flexible protocols and broader inclusion criteria to reflect the diversity of the actual patient population. They help answer practical questions, like which treatment strategy works best for the average person over the long term.

    Modern platforms are making these large-scale studies easier to run. By using tools for remote data collection and telehealth visits, researchers can gather high-quality information from participants in their own communities (learn more about decentralized clinical trial technology on Curebase).

    Who Can Join a Clinical Trial for Multiple Sclerosis Today?

    The face of the MS trial participant is changing, becoming a more accurate reflection of everyone affected by the disease.

    Broadening Diversity and Inclusion

    Historically, MS trials often excluded pediatric and older patients and were made up of predominantly white participants. Today, there is a major push for more inclusive research. Landmark studies are paving the way for a more diverse and representative clinical trial for multiple sclerosis.

    • The PARADIGMS trial was the first major study of a DMT in children and adolescents. It showed that fingolimod reduced relapse rates by a remarkable 82% compared to an older injectable therapy, leading to its approval as the first treatment for pediatric MS.
    • The CHIMES trial was the first study of its kind to exclusively enroll Black and Hispanic patients with MS. It successfully recruited 182 participants, exceeding its target by 25%, and demonstrated that ocrelizumab is highly effective in these historically underrepresented populations.

    These successes show that with focused effort, trial populations can and should reflect the true diversity of the MS community. Modern decentralized clinical trials, which bring the study to the patient, are a key part of this solution, helping to overcome geographical and logistical barriers.

    The Impact of Earlier Diagnosis

    Updates to the diagnostic criteria for MS have also had a huge impact on clinical trials. Modern guidelines, which incorporate MRI findings and other biomarkers, allow for a much earlier and more accurate diagnosis. This means patients can be enrolled in a clinical trial for multiple sclerosis at an earlier stage of their disease, when treatments are often most effective at preventing long term disability.

    Measuring Success: The Endpoints That Matter in MS Trials

    To know if a treatment is working, researchers need to measure its effects. MS trials use a combination of clinical exams, imaging, and biomarkers, typically captured in an integrated EDC, to get a complete picture.

    Clinical and Functional Outcomes

    • EDSS (Expanded Disability Status Scale): This has long been the standard for measuring disability, primarily based on walking ability. An outcome like “confirmed disability progression” is often defined as a sustained increase in the EDSS score over 3 or 6 months.
    • MSFC (MS Functional Composite): To get a broader view of function, the MSFC was developed. It combines three tests: the Timed 25 Foot Walk (leg function), the 9 Hole Peg Test (hand and arm function), and a test of cognitive processing speed.
    • Patient Reported Outcomes (PROs): These are outcomes reported directly by the patient without a clinician’s interpretation. PROs capture the real-world impact of MS on things like fatigue, pain, and quality of life. Collecting this data is easier than ever with electronic platforms and mobile apps, like Curebase’s ePRO/eCOA, which helps sponsors run modern, patient-focused studies.

    Advanced Imaging and Biomarkers

    • MRI Lesion Outcomes: MRI is a powerful tool for seeing disease activity. Trials often track the number of new or enlarging T2 lesions and gadolinium enhancing lesions (areas of active inflammation). A significant reduction in these lesions is an early sign a drug is working. For instance, the BTK inhibitor fenebrutinib showed a greater than 90% reduction in new lesions by just 8 weeks in a Phase 2 trial.
    • Brain Atrophy: MS can cause the brain to lose volume, or shrink, over time. Measuring this “brain atrophy” is now a common secondary endpoint in trials. Slowing the rate of brain volume loss is seen as a sign of a drug’s neuroprotective effects.
    • Optical Coherence Tomography (OCT): OCT is a non invasive scan that takes a high resolution picture of the retina at the back of the eye. Since the retina is an extension of the brain, measuring the thickness of its nerve layers gives researchers a direct window into neurodegeneration.
    • Neurofilament Light Chain (NfL): This is a protein released into the bloodstream when nerve fibers are damaged. A simple blood test can measure NfL levels, providing a real time biomarker of disease activity. Effective treatments have been shown to significantly lower NfL levels, indicating they are protecting the nervous system.

    NEDA: The Goal of Complete Disease Control

    Many trials now report on NEDA, which stands for “No Evidence of Disease Activity”. In its most common form, NEDA-3 is achieved when a patient has no relapses, no new MRI lesions, and no confirmed disability progression over a set period. Achieving NEDA is a high bar, and it’s a strong indicator of long-term success. Teams monitor these composite endpoints in real time with centralized analytics and reporting. In the ULTIMATE trials, 44.6% of patients on ublituximab achieved NEDA-3 over two years, compared to just 12.4% on an older oral therapy.

    Spotlight on Today’s Most Promising Trials

    The current pipeline for MS is incredibly exciting, with research targeting every aspect of the disease.

    Tackling Progressive MS

    For a long time, there were no treatments for progressive forms of MS. A progressive MS trial is uniquely challenging because the disease worsens slowly and steadily, rather than in clear attacks. These trials must run for longer and use endpoints focused on slowing disability progression. The landmark ORATORIO trial was the first to show a therapy, ocrelizumab, could slow disability progression in primary progressive MS, reducing the risk by 24%. This success has opened the door for many more studies in this critical area.

    The Quest for Remyelination

    The ultimate goal in MS is not just to stop the damage but to repair it. Remyelination trials are designed to test therapies that can rebuild the protective myelin sheath around nerves. The first proof of concept came from a small trial of an antihistamine called clemastine, which showed a modest but significant improvement in nerve signal speed, suggesting myelin repair was happening. This field is still young, but it represents a major source of hope for reversing disability.

    A New Class of Drugs: BTK Inhibitors

    One of the most watched areas of research is the BTK inhibitor trial. These oral drugs target Bruton’s Tyrosine Kinase, an enzyme involved in the activity of B cells and microglia, the resident immune cells of the brain. This dual action could potentially quiet both peripheral and central nervous system inflammation.

    • Tolebrutinib and fenebrutinib are two BTK inhibitors in late stage Phase 3 trials for both relapsing and progressive MS. Both have shown powerful effects on reducing MRI lesions in earlier studies. While their development has seen some temporary pauses for safety monitoring related to liver enzymes, these trials continue to move forward and could deliver a new class of oral therapy for all forms of MS.
    • Unfortunately, not all BTK inhibitors have succeeded. The Phase 3 trials for evobrutinib were halted in late 2023 after the drug failed to show it was better than an existing therapy for reducing relapses.

    Following Up for the Long Term

    Finally, it’s crucial to understand how well a treatment works over many years. This is the goal of an extension trial, where participants from an initial study can continue taking the investigational drug. The ublituximab extension trial, following the successful ULTIMATE I & II studies, is providing valuable data showing that the drug’s powerful effects on relapse rates and MRI activity are sustained over the long term.

    The Future is Bright for MS Research

    From more inclusive and adaptive designs to groundbreaking new therapies targeting repair and progression, the world of the clinical trial for multiple sclerosis is transforming. This progress is bringing us closer to a future where MS can be effectively managed, its damage repaired, and its progression halted for every single person.

    By embracing innovative approaches and patient‑centric technologies like eConsent, we can accelerate this journey. To see how modern eClinical solutions are helping researchers run faster, more effective studies, you can learn more about Curebase’s integrated eClinical software.

    Frequently Asked Questions

    What is the main goal of a clinical trial for multiple sclerosis?

    The primary goal is to determine if a new treatment, therapy, or diagnostic method is safe and effective for people with MS. Trials aim to find better ways to reduce relapses, slow disability progression, repair nerve damage, or manage symptoms.

    How have MS clinical trials changed over the years?

    Trials have become much more sophisticated and ethical. Key changes include using active comparators instead of long term placebos, employing adaptive designs to get answers faster, and focusing on more inclusive recruitment to ensure results apply to diverse populations.

    What are common ways success is measured in an MS trial?

    Success is measured using a combination of endpoints. These include clinical measures like relapse rates and disability scores (EDSS), advanced MRI imaging to track lesions and brain volume, and blood biomarkers like Neurofilament Light Chain (NfL) that indicate nerve damage.

    Are there clinical trials for progressive MS?

    Yes. While historically more challenging, there are now many active clinical trials for both primary progressive (PPMS) and secondary progressive (SPMS) MS. These trials focus on endpoints like slowing the steady progression of disability.

    What is the difference between an immunosuppressive and a remyelination trial?

    Most current MS therapies are immunosuppressive, meaning they work by calming or suppressing the immune system to prevent it from attacking the brain and spinal cord. A remyelination trial, on the other hand, tests drugs designed to actively repair the damaged myelin sheath, with the goal of restoring nerve function.

    How can I find a clinical trial for multiple sclerosis?

    You can speak with your neurologist, who is often aware of recruiting studies. Additionally, websites like ClinicalTrials.gov and the National MS Society provide searchable databases of ongoing trials. Platforms that support decentralized clinical trials are also making it easier for patients to participate from anywhere, so it is always worth exploring your options. Or talk to our team to learn what’s possible.